Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing
18 August 2022
| COVID-19: Vaccines
Overview
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
This document has been updated: Version 18 August 2022.
For translations of this document in other languages, click here.
Related documents:
Archived versions:
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. Version 21 January 2022.
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. Version 19 November 2021.
- Interim recommendations for use of the Pfizer–BioNTech BNT162b2 vaccine. Version 15 June 2021.
- Interim recommendations for use of the Pfizer–BioNTech BNT162b2 vaccine. Version 8 January 2021.
WHO Team
Agenda, Policy & Strategy (APS),
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization
Editors
WHO
Number of pages
16
Reference numbers
WHO Reference Number: WHO-2019-nCoV-vaccines-SAGE-recommendation-BNT162b2-2022.1-eng.pdf
Copyright
